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Abstract: Chronic inflammatory diseases affect millions of people globally and the incidence rate
is on the rise. While inflammation contributes to the tissue healing process, chronic inflammation
can lead to life-long debilitation and loss of tissue function and organ failure. Chronic inflammatory
diseases include hepatic, gastrointestinal and neurodegenerative complications which can lead
to malignancy. Despite the millennial advancements in diagnostic and therapeutic modalities,
there remains no effective cure for patients who suffer from inflammatory diseases. Therefore,
patients seek alternatives and complementary agents as adjunct therapies to relieve symptoms and
possibly to prevent consequences of inflammation. It is well known that green tea polyphenols (GrTPs)
are potent antioxidants with important roles in regulating vital signaling pathways. These comprise
transcription nuclear factor-kappa B mediated I kappa B kinase complex pathways, programmed cell
death pathways like caspases and B-cell lymphoma-2 and intervention with the surge of inflammatory
markers like cytokines and production ofcyclooxygenase-2. This paper concisely reviews relevant
investigations regarding protective effects of GrTPs and some reported adverse effects, as well as
possible applications for GrTPs in the treatment of chronic and inflammatory complications.
Keywords: chronic inflammatory diseases; green tea polyphenols; (−)-Epigallocatechin-3-gallate
(EGCG)
1. Introduction
Chronic inflammatory diseases affect millions of people and the incidence rate is on the rise.
While inflammation contributes to the tissue healing process, chronic inflammation can lead to
life-long debilitation and loss of tissue function and organ failure. Tumor necrosis factor α (TNFα)
is a proinflammatory cytokine that promotes various chemokines and cytokines to commence acute
and chronic stages of inflammation. TNFα is released chiefly by activated macrophages, astroglia,
microglia, CD4+ lymphocytes, natural killer cells (NK), and neurons [1–3]. TNFα release is connected
with inflammation and pain related sensation in patients with inflammatory diseases like hepatitis,
inflammatory bowel disease, pancreatitis, and neuropathic complications [4]. TNFα is known to
contribute to the progression of neuropathic pains [5]. Soluble TNF receptors (R1 and R2) are
capable of neutralizing TNFα circulation to improve pain related responses to mechanical and
thermal hypersensitivity or peripheral nerve injuries [6,7]. TNFα reveals vital functions in the
pathogenesis of inflammatory diseases, as inhibition of TNFα ameliorates the duration of experimental
pancreatitis [2,8,9]. Genetic manipulation such as TNFα receptor 1 (TNFR1) gene deletion and anti-TNF
monoclonal antibodies’ (e.g., etanercept) application improve acute inflammation in animal models [8].
Although current clinical applications to use these biological drugs may ease the inflammatory cascades
and pain by reducing TNFα and other cytokines, the inflammation and pain are likely to re-surface
in the patients who suffer from autoimmune diseases including arthritis and inflammatory bowel
disease [7,10]. In addition, anti-TNFαmonoclonal antibodies are economically unfeasible (expensive)
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and administration can cause potential complications [11] to provoke severe infectious diseases with
viral (JC virus disease), fungal (aspergillosis) and microbial (tuberculosis) agents.
Inflammatory diseases include metabolic syndrome, nonalcoholic hepatitis, neurodegenerative
diseases and gastrointestinal complications which can lead to malignancy. Indeed, the gut comprises
major neuronal systems in the body and neurodegenerative disorders (e.g., Parkinson’s and
Alzheimer’s) are commonly manifested with severe gastrointestinal complications. With the millennial
advancements in diagnostic as well as anti-inflammatory therapeutic modalities (e.g., biological
therapies, anti-TNFαmonoclonal antibodies), there remains no effective cure available for those who
suffer from chronic inflammatory diseases. Therefore, patients seek alternatives and complementary
medications to relieve the symptoms and possibly to prevent consequences of inflammatory diseases.
Yet, the safety and efficacy of these agents are not fully known as well as their possible interaction with
the standard-of-care therapies. Thus, the consequences can become life-threatening, from uptake of
contaminated toxic metals to complex interactions with conventional therapies [10].
Regular consumption of tea and plants rich in polyphenols are known for various
health-promoting functions such as diuretic, anticarcinogenic, immunity-support, antimicrobial, and
anti-inflammatory effects. Different relevant investigations have revealed green tea polyphenols
as potent antioxidants [12,13] to play important roles in inactivation of several signaling pathways
involved in inflammation. These include transcription nuclear factor-kappa B (NF-κB) mediated I
kappa B kinase complex (IKK) pathways [14], TNFα [9,12,13], downregulation of cyclooxygenase
(Cox)-2and B-cell lymphoma-2 (Bcl-2) activities [15], and upregulation of protective programmed cell
death pathways [16,17]. Clinical trials and meta-analyses reveal constant consumption of diets rich
in polyphenols to protect against chronic inflammatory diseases including cardiovascular [18] and
neurodegenerative diseases [19] in humans. Consumption of a polyphenol-rich diet is linked with
elevated plasma antioxidant [20], lowered markers for oxidative stress [21] and improved albuminuria
in diabetic patients [22]. Additionally, polyphenols’ use includes possible production of safe plastics,
nanomaterials and storage for food products. Recent studies reveal an attractive field for the possible
use of these natural extracts in biopolymer formulations [23]. Polyphenols with antioxidant and
antimicrobial activities are candidates for use as active compounds in bio-additives for food packaging
materials to reduce the oxidation and deterioration of food [23–26] and to prevent spoilage and
contamination with infectious pathogens. For instance, dibutyltin dichloride, a stabilizer used in the
production of polyvinyl chloride plastics, can cause severe inflammatory complications including
pancreatitis in animal models [2]. Another organic synthetic compound, bisphenol A (BPA), is utilized
to produce plastics for food packaging which has the potential to disrupt endocrine hormones and to
increase the risk for type 2 diabetes [27]. Polyphenolic use, as a natural packaging product, is a novel
venue to replace these synthetic compounds and additives with indications of severe side effects in
consumers, including elevation of chronic inflammatory complications and malignancies [2,24–27].
This paper reviews an insight into some of the relevant investigations regarding protective effects
of green tea polyphenols and their possible applications in the treatment of chronic and inflammatory
diseases. Additionally, this paper briefly discusses some of the reported side effects due to consumption
of these polyphenols.
2. Green Tea and Polyphenols
Leaves from Camellia Sinensis shrub form three types of teas including black tea, green tea and
oolong tea, depending on their processing techniques. Green tea is prepared by steaming and drying
the tealeaves (20% of total production). Tea extracts are commonly used as beverages, food additives
or integrated into cosmetic and pharmaceutical formulations [20]. Tea extracts are rich in vitamins
(B and C), minerals, polyphenols, caffeic acid, fertaric acid, tannins and volatiles. These polyphenols
have been investigated for various biological and physiological activities. Tea extracts are used as
coloring agents, antioxidants, and nutritional additives. Polyphenols have phenolic molecules and
polymeric structures [28]. Polyphenols are ubiquitous secondary metabolites in tea and some other
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plants [29] and contribute to pigmentation in plant organs. Polyphenols play an important role as the
mechanism of defense against environmental and biological stressors including in response to fungal
and other pathogens’ attacks [16]. Polyphenols have been shown to protect against oxidative damage
by inhibiting the formation of free radicals and reactive oxygen species (ROS).
The purified green tea polyphenols contain >95% polyphenols when analyzed with
high-performance liquid chromatography (HPLC). Pure GrTP extracts contain the following percentage
composition of polyphenols (each catechin): (−)-epicatechin (EC) 35%, (−)-epigallocatechin (EGC) 15%,
(−)-epicatechin-gallate (ECG) 4%, and (−)-epigallocatechin-3-gallate (EGCG) 38–40% [9]. The molecular
structure of EGCG and EC, two of the most abundant GrTPs, are presented in the Figure 1.
The most prevalent individual polyphenolic constituent, EGCG (98% purity), is believed to
account for several therapeutic effects of polyphenols. For instance, GrTPs are reported to attenuate
inflammation in different inflammatory bowel disease models [9,13,17,30,31]. Following ingestion,
GrTPs are extensively dispersed amongst the organs, including the hepatic system [32]. However,
the anti-inflammatory effects of GrTPs are not limited to the scavenging of toxic oxidants, as GrTPs,
specifically EGCG, can block the activation of the NF-κB and the release of proinflammatory TNFα in
intestinal epithelia [14]. The ability of GrTPs to inhibit NF-κB activation and release of TNFα can be
responsible for the anti-inflammatory effects of tea consumption.
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3. Inflammatory Bowel Disease and Green Tea Polyphenols
Crohn’s disease and ulcerative colitis are known chronic idiopathic inflammatory bowel diseases
(IBD) mediated by immune dysregulation. In a normal gut, the number of intestinal epithelial cells
(IEC) is tightly regulated to cov r the surface of villi and crypts. IEC ar generat d by stem cells in the
crypts which differentiate and migrate to the tip of villi then are “sloughed off” in approximately two to
three days [15,33–35] and replaced with brand new epithelial cells. Therefore, the ratio of villus height
in crypt stays in a constant state as it is regulated by the apoptosis (death) pathways [17]. Defective
apoptosis impairs intestinal epithelial barri r function, activates immune system and macrophages,
increases production of proinflammatory cytokines like TNFα and leads to IBD [17,35,36]. In Crohn’s
patients, the lamina propria lymphocytes (LPL) in intestinal mucosa are chronically activated [35] with
increased expression of anti-apoptotic molecules [37]. Dysregulated apoptosis in IEC and activated
LPL are k y pathognomonic mechanisms for IBD. Further, ROS are increased in IBD patients and
implicated as mediators of intestinal inflammation [9,35].
Despite available targeted therapies and advancements in the humanized monoclonal antibodies
and complementary and alternative agents [9,35], the consequences are not yet fully explored.
Sulfasalazine is a standard of therapy and commonly used in IBD patients. Yet, it has severe adverse
effects, such as pulmonary fibrosis, infertility, and lack of response, which ultimately leads to intestinal
resection in these patients. In a bold animal study, green tea polyphenols (GrTP, EGCG) were compared
to sulfasalazine for their anti-inflammatory properties. Wild type mice were given dextran sodium
sulfate (DSS) for a chemically induced ulcerative colitis model [13]. Interleukin-10 (IL-10) deficient
mice spontaneously develop IBD when exposed to the normal gut microbiota from their control
wild type background to provoke enterocolitis similar to Crohn’s disease. Colitis and enterocolitis
animals tolerated treatments with GrTP, EGCG, or sulfasalazine which was added into the diets.
Treated animals similarly developed less severe symptoms compared to the sham-treated animals.
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The inflammatory markers (TNFα, IL-6, serum amyloid A) were significantly upregulated along
with pathological symptoms but drastically decreased with GrTP, EGCG or sulfasalazine treatment.
While hepatic and colonic antioxidants (glutathione, cysteine) are depleted in IBD patients and colitic
models [9,13], GrTP and EGCG significantly restored antioxidant concentrations and attenuated colitis
symptoms similar to sulfasalazine administration [9]. In addition, GrTP decreased disease activity
and inhibited inflammatory responses in interleukin-2-deficient (IL-2−/−) mouse models for chronic
inflammatory disease [31]. Colonic explants and LPL cultures from GrTP-treated mice had decreased
spontaneous interferon-gamma and TNFα secretions [31]. In another study, lymphocytes from IBD
patients and healthy subjects were chemically damaged (hydrogen peroxide) in vitro and then treated
with epicatechin (0–0.1 mg/mL). A significant reduction in induced-DNA damage was discovered in
lymphocytes from patients (48.6%) and normal controls (35.2%) when compared with lymphocytes
from untreated subjects (both p < 0.001). Therefore, epicatechin significantly decreased oxidative stress
in lymphocytes and supported beneficial effects of epicatechin inclusion in diets for IBD patients [38].
IKK mediates activation of NF-κB cascade in inflammatory responses to release the
proinflammatory cytokine, TNFα. In vitro studies using GrTP and EGCG have shown a series
of anti-inflammatory activities by inhibiting NF-κB through inactivation of I-κB kinase complex
in intestinal epithelia cells. Pretreatment of intestinal cells with GrTPs (0.4 mg/mL) diminished
TNFα-induced IKK and NF-κB activity [14]. The gallate group from polyphenols was required to
block TNFα initiated IKK activation. When intestinal epithelial cells were transiently transfected
with NF-κB-inducing kinase (NIK) for continued IKK activation, EGCG significantly decreased IKK
activity in these NIK transfected epithelia [14]. Therefore, GrTP and specifically EGCG, but not other
polyphenols (EC, EGC, ECG), were reported as effective inhibitors of IKK activity and as natural
anti-inflammatory agents [14]. In a case-control study of 678 ulcerative colitis patients (2008–2013),
increased risk for colitis was associated with serial factors as follow: (1) irregular meal times (OR:
2.287; 95% CI: 1.494–3.825); (2) consumption of fried (OR: 1.920; 95% CI: 1.253–3.254); (3) salty (OR:
1.465; 95% CI: 1.046–2.726) and frozen dinners (OR: 1.868; 95% CI: 1.392–2.854); (4) intestinal infectious
diseases (1–2/year, OR: 1.836; 95% CI: 1.182–2.641); (5) frequent use of drugs such as antibiotics and
NSAIDs (OR: 2.893; 95% CI: 1.619–5.312); (6) and high work stressors (OR: 1.732; 95% CI: 1.142–2.628,
p < 0.05). In contrast, drinking tea (OR: 0.338, 95% CI: 0.275–0.488) and physical activities (1–2/week,
OR: 0.655, 95% CI: 0.391–0.788; ≥3 times/week, OR: 0.461, 95% CI: 0.319–0.672, p < 0.05) were linked
with significant protective effects in these patients [39]. These studies support possible beneficial
effects of GrTP inclusion in diets for IBD patients.
4. Gastrointestinal Associated Malignancies and Green Tea Polyphenols
Cancer is one of the most prevalent causes of morbidity and mortality. Additionally, cancer
patients are at risk for developing severe complications including diarrhea, nausea and abdominal
pain during chemotherapy, mainly due to cytotoxic effects of anticancer drugs [17]. Studies suggest a
protective effect of tea consumption on malignancies including those with gastrointestinal involvement
mainly based on animal trials and in vitro studies. Yet, strong clinical trials and investigations are
lacking to support the anticancer effects. GrTP is shown to inhibit carcinogen-induced gastrointestinal
tumors in rodents [40–44] and in abnormal cell growth to induce apoptosis in various carcinoma
cell lines [17,45,46]. GrTP and EGCG were proven to regulate apoptosis in the intestinal epithelia.
In a normal gut, highly organized epithelial cells cover surfaces of villi and crypts. The number
of IEC which blanket the normal gut is tightly regulated by programmed cell death (apoptosis)
pathways. Dysregulated and defective apoptosis lead to IEC overgrowth and severe consequences
including malignancy. Apoptosis “programmed cell death” is a process of self-destruction that can be
initiated via extrinsic and intrinsic pathways. In the gut, extrinsic pathway leads to Fas-associated
death domain proteins (FADD) and enzymatic activities of cysteine-aspartate specific proteases
“caspasescascades” [47]. When IEC were treated with GrTP (0.4–0.8 mg/mL), they induced DNA
fragmentation in a dose responsive fashion [17]. In higher concentrations (>0.8 mg/mL), GrTP
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caused a mixture of cytolysis and apoptosis. In addition, epithelial cells exposed to GrTP and EGCG,
but not other polyphenols (i.e., EC, EGC), had increased caspase-3, caspase-8 and caspase-9 activities;
but caspase inhibitors could rescue cells from imminent apoptosis [17]. Furthermore, GrTP caused
activation of Fas-associated proteins with FADD recruitment to Fas/CD95 domains. Indeed, GrTP
blocked NF-κB activation, yet NF-κB inhibitor (MG132) only promoted cytolysis and not apoptosis.
GrTP- and EGCG-induced apoptosis in intestinal epithelia and the activation of death pathways
mediated by the caspase-8 through FADD dependent pathways [17] are presenting promising results
as possible anticancer agents. In a meta-analysis of 6123 gastric cancer cases and 134,006 controls,
green tea consumption had a minor inverse association with risk of gastric cancer (OR = 0.68, 95% CI
= 0.49–0.92). A consumption of up to five cups per day of green tea was reported safe (OR = 0.99,
95% CI = 0.78–1.27) and to prevent gastric cancer [48]. A recent case-control survey trial studied the
risk factor for gastric cancer and tea consumption. Similarly, this investigation indicated protective
effects of regular tea consumption (OR 0.72; CI 95%) and in a large amount (≥35 g/week) (OR 0.53;
CI 95%) against gastric malignancy [49]. Future investigations may reveal use for GrTPs and EGCG as
adjuvant therapies in malignancies.
5. Hepatic Complications and Green Tea Polyphenols
Acetaminophen [N-acetyl-p-aminophenol (APAP)] has been widely used as an over the counter
anti-pyretic and analgesic drug since 1955. APAP overdose is a common cause of acute hepatic
failure and mortality. APAP overdose is indicated in 50% of acute hepatic failures and approximately
20% of the liver transplant cases in the USA [50]. APAP-induced liver toxicity acts through many
factors, including generation of ROS, glutathione (GSH) depletion, upregulation of apoptosis and
Cox-2 generation, and inflammatory cytokines production. Generation of ROS causes tissue damage.
GSH is a tripeptide and a powerful source of endogenous antioxidants which counteracts against the
destructive deposits of free radicals. Yet, GSH sources in liver become depleted due to APAP to cause
hepatotoxicity and inflammatory complications.
Current antidote practice is the use of the antioxidant Nacetylcystiene (NAC), which may not
be always effective [50]. Therefore, more efficient compounds are urgently needed to protect against
hepatic failure, death or liver transplants. In an investigation, mice were given a toxic dose of
APAP (0.75 mg/g) by oral gavage. Animals developed profound up regulation of inflammatory
markers, TNFα and Serum Amyloid A (SAA) release, as well as Cox-2 activities and Bcl-2 production.
The inflammatory markers caused extensive centrilobular apoptosis, necrosis, and severe infiltration
of leukocytes accompanied with generation of ROS and depletion of hepatic GSH concentration.
GrTP supplementation in the diet prior to APAP injection significantly improved concentration of
hepatic GSH, attenuated inflammatory markers, liver lesions and down regulated Cox-2 and Bcl-2
expression. In addition, GrTP normalized pathologically elevated hepatic enzyme activity of alanine
aminotransferase (ALT) released by damaged hepatocytes, and protected against liver injury. Therefore,
GrTP attenuated hepatotoxicity through normalizing antioxidants, inflammatory markers and Cox-2
and Bcl-2 activation [12,15], suggesting a potential for GrTP additives protecting against APAP toxicity.
As unhealthy diet and inactivity in urban areas are on the rise in recent decades, as are the health
consequences including metabolic syndrome, the obesity epidemic and fatty liver inflammation to trigger
further unforeseen socio-economic burdens. Looking for a magic wand would be a simple, effective,
safe and feasible dietary compound to alleviate these public health loads. EGCG has been reported to
show putative health effects including protection against inflammation and obesity. In a dose dependent
study, inclusion of high dose (1.3 mg/g) EGCG in daily diets caused weight loss in DSS-treated BALB/c
mice [9]. Recently, another study used very high doses of EGCG (3.2 mg/g) for three days in the same
model (DSS-treated mice) and reported decreased colonic lipid peroxides and gut permeability and
enhanced body weight loss [51]. Therefore, high dose EGCG might have different effects, including
being responsible for lowering digestion of consumed protein and lipid and its possible application in
obesity and weight loss patients. In addition, very high doses of EGCG require further safety trials.
Nutrients 2017, 9, 561 6 of 14
Nonalcoholic fatty liver disease (NASH) is manifested with obesity and other complications
with severe life threatening consequences. EGCG (0.05 mg/g/day) oral gavage regulated hepatic
mitochondrial respiratory cascades and improved lipid metabolism, and insulin sensitivity in obese
mice [52]. EGCG increased energy expenditure, and prevented oxidation of lipid substrates-stimulated
by mitochondria and hepatic steatosis in this obesity model. EGCG is reported to specifically inhibit
activated hepatic stellate cells by upregulating de novo biosynthesis of GSH [53]. Further, GrTP is
reported to protect against NASH by decreasing hepatic steatosis and NF-κB activation in a model on
a high fat diet given for eight weeks [54]. GrTP attenuated prostaglandin E2 (PGE2) accumulation and
lipid peroxidation to reduce Cox-2 activity which was independent of arachidonic acid. GrTP protected
against hepatic damage induced by a high fat diet in obese rats [54]. GrTP (10–20 mg/g) normalized
liver malondialdehyde without affecting cytochrome P450 2E1 mRNA expression, and decreased
upregulated hepatic Cox-2 activity and PGE2 elevated levels provoked by the high fat diet. In addition,
GrTP attenuated increases in total hepatic short chain fatty acids without affecting the n-6/n-3 ratio and
decreased total liver arachidonic acid [54]. Additionally, a double-blind, randomized clinical trial was
reported in NASH patients with diagnostic ultrasonography symptoms and elevated hepatic enzymes,
ALT >31 mg/dL and AST >41 mg/dL, respectively. Subjects were given green tea extract (500 mg
tablet/day) or placebo for 90 days. Green tea significantly decreased hepatic enzymes; ALT and
AST compared to placebo p < 0.001 [55]. In another randomized, double-blind trial, diabetic subjects
with albuminuria received GrTP (containing 800mg of epigallocatechin-3-gallate) supplements for
12 consecutive weeks in addition to their standard of care therapy. Patients who received green tea
polyphenol supplements showed significant improvements in urinary albumin-creatinine ratio (41%
p = 0.019) compared to the placebo (standard therapy alone) group [22]. Further investigations may
support the use of GrTPs in diabetic subjects and their hepatic complications including hepatotoxicity
and fatty liver, as well as application in weight loss programs in obesity subjects.
6. Neurodegenerative Disorders and Green Tea Polyphenols
Neurodegeneration is associated with central nervous system (CNS) disorders, such as Parkinson’s
and Alzheimer’s diseases, which are caused by multiple environmental and genetic factors [56].
Neurodegenerative disorders are commonly associated with severe gastrointestinal complications, as the
gut is comprised of complex neuronal systems. Alzheimer’s disease is a progressive neurodegenerative
disorder characterized by amyloid β plaques formation, neurofibrillary tangles, microglial and astroglial
activation leading to neuronal dysfunction and death. Microglia are primary immune cells which
release proinflammatory cytokines (e.g., TNFα) and neurotoxins in the brain and contribute to
neuroinflammation [1]. Neuroinflammation is a hallmark for Alzheimer’s disease. Current therapies
primarily focus on symptomatic improvement of cholinergic transmission. A mechanism by which to
provide neuroprotection [19] and to prevent microglial activation may be useful in the treatment of
Alzheimer’s. EGCG was reported to protect neuronal cells from microglia-induced cytotoxicity and
to suppress amyloid β-induced TNFα release [57]. Parkinson’s disease, the second most prevalent
neurodegenerative disease, is characterized by the loss of the neurotransmitter dopamine and neuronal
degeneration in the substantia nigra. Studies revealed EGCG to improve dopaminaergic degeneration
and may be beneficial for Parkinson’s patients [58]. In a rat model for Parkinson’s, green tea extract
or EGCG reversed pathological and behavioral modifications, demonstrating neuroprotection by
decreasing rotational and increased locomotor activities. Additionally, green tea extracts and EGCG
improved cognitive dysfunction by antioxidant and anti-inflammatory properties [59]. In a double
blinded, randomized trial, daily consumption of 2000 mg green tea powder (containing 220 mg of
catechins) for 12 months did not significantly improve cognitive function in elderly Japanese (nursing
home) participants [21]. However, levels of markers for oxidative stress, malondialdehyde-modified
low-density lipoprotein, were significantly lower in the green tea group (OR −1.73, 95% CI, p = 0.04)
compared to those in the placebo arm [21].
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Table 1. Chronic inflammatory diseases and tea. Table summarizes applied investigations into green tea and polyphenols against different chronic inflammatory
diseases using in in vitro, in vivo and in human trials. EGCG: epigallocatechin-3-gallate; GrTP: green tea polyphenols; IEC: intestinal epithelial cells; WT: wildtype
mice, IL-/- : interleukin knockout mice; APAP: acetaminophen.
Applied Investigations Tea Extract, GrTP, EGCG In Vitro/Animal/Human Trial References
Inflammatory Bowel Disease
GrTP DSS-WT mouse model Oz et al. [13]
GrTP, EGCG IL-10-/- spontaneous and DSS-WT Oz et al. [9]
GrTP IL-2-/-spontaneous Varilek et al. [31]
Tea consumption Patients Niu J et al. [39]
in vitro (patients with lymphocytes) Najafzadeh et al. [38]
GrTP, EGCG, EGC, ECG in vitro IEC Yang et al. [14]
GI malignancy/prevention Tea extract WT-mice, rats Ju et al. [40], Metz et al. [41]; Issa et al. [42], Ohishi et al. [43]
GrTP, EGCG in vitrocell lines Oz et al. [17], Isemura et al. [44], Wu [45], Basu et al. [46]
Tea consumption Human subjects Zhou et al. [48]
Hepatic complications GrTP WT-mice and APAP toxicity Oz et al. [12,15]
NASH GrTP Rat model Chung et al. [54]
Diabetic Tea extract Patients Borges et al. [22]
Metabolicweight loss, EGCG WT-mice Oz et al. [9], Bitzer et al. [51], Santamarina et al. [52]
Fatty liver disease WT-mice Hirsch et al. [60]
Neurodegenerative Disorders
Alzheimer‘s. EGCG in vitro neuronal cells Cheng-Chung et al. [57]
Parkinson‘s disease EGCG Patients Renaud et al. [58]
EGCG Rat model Bitu et al. [59]
Cognitive function Tea extract Elderly Ide et al. [21]
Diabetic retinopathy Green tea Human subjects Ma et al. [61]
Retinalneurodegeneration EGCG Tat retina Yang et al. [62]
Stroke EGCG WT-mice Bai et al. [63], Zhang et al. [64]
Tea consumption Human subjects Pang et al. [65]
Autism spectrum Tea extract WT-mice pups Banji D et al. [66]
Tea and Side effects
EGCG Human subjects Chow et al. [67]
Weight loss GrTP, EGCG WT-mice Oz et al. [9], Bitzer et al. [51]
Microbia, toxic metal contaminant Tea Ting et al. [68]
Microbial contaminant/ provocation Tea consumption Human subjects Lessa et al. [69], Evans et al. [70]
Gastroesophageal reflux disease Tea consumption Human subjects Vossoughinia et al. [71]
Iron deficiency EGCG WT-mice Yeoh et al. [72]
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Retinal neurodegeneration is a major cause of blindness specifically in the elderly population.
Diabetic retinopathy is a recurrent complication of diabetes (type 1, type 2) which results in increased
inflammation, oxidative stress, and vascular dysfunction. The inflammation and neurodegeneration
may occur even before the development of clinical signs of diabetes. During the process of diabetes,
the retina triggering proinflammatory signaling pathways becomes chronically activated, leading to
retinal neurodegeneration and the loss of vision [61]. In a case-control clinical trial, 100 patients with
diabetic retinopathy were recruited along with 100 age- and sex-matched diabetic controls without
retinopathy in China. Diabetic retinopathy was confirmed from retinal photographs and the pattern
of green tea consumption was collected using a face-to-face interview. The odds ratio for green tea
consumption for diabetic retinopathy patients was 0.49 (95% CI: 0.26–0.90). When stratified by sex,
the green tea consumption and protective effect of green tea on retinopathy was more significant
in female (p = 0.01) than male participants (p = 0.63). When adjusted for age and sex, green tea
consumption was reported to be significantly associated with reversed diabetic retinopathy (OR = 0.48;
p = 0.04), high systolic blood pressure (OR = 1.02; p = 0.05), duration of diabetes (OR = 1.07; p = 0.02),
and the presence of family history of diabetes (OR = 2.35; p = 0.04). Therefore, those diabetic patients
who regularly consumed green tea (for at least one year) had a significant retinopathy risk reduction
of about 50% compared with those who had not.
EGCG with potent antioxidants is reported to neuroprotect outer retinal degeneration after
sodium iodate insult [62]. Indeed, EGCG has at least twice the antioxidant potential of vitamin E or
C [59]. The retinal protection with orally administered EGCG was linked with reduced expression of
superoxide dismutase, GSH peroxidase, caspase-3 and suppression of 8-iso-prostaglandin generation
in the retina [73], suggesting a possible therapeutic/maintenance action of EGCG in these inflammatory
neurodegenerative diseases.
Stroke is a major cerebrovascular disease which results in disability and mortality, thus far
with inadequate neuroprotective and neurotherapeutic agents. Tissue plasminogen activator (t-PA)
is the only United States Food and Drug Administration (FDA)-approved therapy against acute
ischemic stroke. Yet, clinical outcomes of t-PA depend on its short therapeutic period and grave
adverse effects, such as neurotoxicity and hemorrhagic transformation. Adjuvant therapies such
as EGCG may reduce the side effects and improve the outcomes [64]. EGCG has anti-angiogenic
properties and a possible preventive effect against ischemic stroke via the nuclear factor erythroid
2-related factor 2 (Nrf2) signaling pathway. EGCG therapy for the acute phase of ischemic stroke
has been reported to promote angiogenesis in a mouse model of transient middle cerebral artery
occlusion (MCAO), conceivably by upregulating the Nrf2 signaling pathway [65]. Additionally,
EGCG was shown to augment proliferation and differentiation of neural progenitor cells (NPCs)
isolated from the ipsilateral subventricular zone with subsequent spontaneous recovery after ischemic
stroke [64]. In a meta-analysis, 259,267 individuals were included from nine different clinical trials [65].
The amount of green tea consumption had a negative correlation with intracerebral hemorrhage and
cerebral infarction. The risk increased for intracerebral hemorrhage (OR = 1.24, 95% CI: 1.03–1.49) and
cerebral infarction (OR = 1.15, 95% CI: 1.01–1.30) in those who did not consume green tea, compared to
those consuming more than one cup of green tea per day. The risk reduced for myocardial infarction
(OR = 0.81, 95% CI: 0.67–0.98) and stroke (OR = 0.64, 95% CI: 0.47–0.86) for one to three cups of green
tea consumed per day, compared to those who drank less than one cup per day. Likewise, those
drinking four or more cups per day had a reduced risk of myocardial infarction (OR = 0.68, 95% CI:
0.56–0.84) compared to those who drank less than one cup per day [65]. Taken together, green tea and
EGCG may exert a beneficial effect on neurogenesis, stroke recovery and prevention.
Prenatal and postnatal contact with toxic elements can cause severe consequences in newborns.
Postnatal exposure of two–week-old mice pups to a single dose of valproate (0.4 mg/g subcutaneous)
provokes experimental autism spectrum and related neurobehavioral abnormalities. Valproate exposed
pups were treated daily with green tea extract (0.075 or 0.3 mg/g) orally for about four weeks [66].
Extensive behavioral improvements (nociceptive response, locomotion, anxiety, motor co-ordination)
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were detected particularly in those pups treated with 0.3 mg/g green tea extract. These modifications
were consistent with reduction in oxidative stress formation as well as neuronal cytoprotection.
The antioxidant prosperity of green tea polyphenols suggests a possible application in autism spectrum
patients. Table 1 summarizes applied investigations into green tea and polyphenols against different
chronic inflammatory diseases.
7. Tea Polyphenols and Possible Side Effects
Tea, a popular beverage, has been consumed for many centuries. A preclinical trial described
EGCG to have no detectable side effects at 800 mg/day in subjects [67]. However, some deleterious
effects of tea and its GrTPs are as follows: tea is a known diuretic agent; overuse may result in
dehydration. Prolonged GrTP supplementation may alter bile acid synthesis and increase hepatic
oxidative stress with inflammatory hepatic injury, as reported in mice fed high cholesterol diets [60].
Weight loss may be considered a beneficial as well as a side effect of high dose GrTP (2.6 mg/g [9])
and EGCG consumption (1.3 mg/g [9], 3.2 mg/g [51]). Although tea has antimicrobial and antifungal
properties, different toxic metals [68] and microbial contaminations such as Clostridial spp. have been
isolated from unpasteurized tea [68].
Clostridium difficle (C. diff ) is a facultative gram negative microbial which can cause recurrent and
life threatening complications in about 0.2% of the population [69]. The recent increase in rates of
recurrent C. diff was associated with tea consumption in the vulnerable group. A recent retrospective
clinical trial in C. diff patients (Veteran Administration hospitals) with recurrent infection who drank
tea showed the possible antimicrobial effects of tea. It was suggested that tea in the gut of these
patients may reduce the normal microbiome and provoke overgrowth of the facultative pathogens [70].
However, the low number of participants in this trial requires further in-depth investigations to confirm
these findings.
Gastroesophageal reflux disease (GERD) is a common chronic inflammatory disease characterized
by persistent regurgitation and heartburn with increased prevalence in recent years. In a trial risk,
factors were evaluated in 1685 participants. Of these, 420 (26%) suffered from GERD symptoms and
the risk factors with significant effects coincided with the use of tea, coffee, smoking, NSAIDs and
food indulgence [71]. The risk factors seemed to be similar to other previously reported trials, but the
prevalence was remarkably higher among the studied group [71].
Finally, EGCG is counter-regulated by the presence of iron and lipocalin 2. EGCG prevents the
peroxidase-catalyzed reaction by reverting the reactive peroxidase heme (compound I: oxoiron) back to
its native inactive ferric state, possibly via the exchange of electrons [72]. Therefore, dietary oral intake
of iron tablets can diminish EGCG, rendering it to become ineffective in inhibiting myeloperoxidase
activity as an antioxidant to establish mucosal protection and anti-inflammatory effects of EGCG.
8. Conclusions
Chronic inflammatory diseases affect many humans worldwide, yet there is no available cure.
Tea is one of the most consumed beverages globally and has been around for over 10,000 years.
The polyphenols have shown varieties of possible applications, including increasing antioxidants
(e.g., GSH, cysteine) depots in vital organs [9,13,35,53] and protecting against chronic inflammation in
in vivo and in vitro models [31]. Studies revealed GrTPs attenuate inflammatory responses in signaling
pathways, by downregulating IKK, NF-κB (0.4 mg/mL [14]), cytokines like TNFα, inflammatory
markers [9,12–15,35,39], Cox-2 and Bcl-2, to protect against hepatic [12–15] and colonic [9,31,38,39]
neurodegenerative complications [57–59,61–66,73,74] and various anti-malignancy effects [40–46,48,49].
Importantly, studies have revealed that GrTPs act dose dependently, as high doses (0.4–0.8 mg/mL)
activate apoptotic pathways through caspases and DNA breakdown to provoke anti-malignant
effects [17]. Also, GrTPs promote weight loss in high doses (EGCG 1.3mg/g/daily [9], 3.2 mg/g
every three days [51]) which can be beneficial for the regulation of hepatic enzymes (10–20 mg/g [54])
and metabolism (500 mg tablet/day [55]), as well as in metabolic syndrome and obesity (EGCG 0.05
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mg/g [52]); yet, this is a side effect in certain situations where weight loss is not favored. In addition,
GrTPs and EGCG in very high doses (3.2 mg/g) require further safety trials. It is a common belief
that constant consumption of tea provides anti-inflammatory and cardiovascular beneficial effects.
Whether tea and its polyphenols provide preventive or therapeutic effects requires supporting clinical
trials. In the era of antibiotic resistance and the hospital superbug epidemic, the use of GrTPs as natural
antimicrobial and antifungal agents is an attractive area to be explored. However, GrTPs natural
antimicrobial status that possibly alters the gut microbiome may be perceived as an adverse effect with
can support facultative C. diff in certain vulnerable populations [70]. These warnings against GrTP
utilization requires further in-depth trials before any recommendations can be implemented. Finally,
GrTP has an attractive potential for use as a natural packaging material [23–26] to replace synthetic
compounds with possible severe side effects by promoting chronic inflammation and malignancies in
consumers [2,24,27].
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